NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 66 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $962,813 | +18.9% | 1,160,016 | +0.3% | 0.00% | – |
| Q1 2023 | $809,791 | -2.0% | 1,156,845 | -28.8% | 0.00% | – |
| Q4 2022 | $826,562 | +638.0% | 1,623,893 | +823.4% | 0.00% | – |
| Q3 2022 | $112,000 | -42.3% | 175,862 | -6.5% | 0.00% | – |
| Q2 2022 | $194,000 | -51.4% | 188,040 | -11.5% | 0.00% | – |
| Q1 2022 | $399,000 | -56.9% | 212,530 | +10.7% | 0.00% | – |
| Q4 2021 | $925,000 | -31.9% | 191,925 | +2.1% | 0.00% | – |
| Q3 2021 | $1,359,000 | -20.1% | 187,958 | +2.0% | 0.00% | – |
| Q2 2021 | $1,700,000 | +335.9% | 184,214 | +481.9% | 0.00% | – |
| Q1 2021 | $390,000 | +21.1% | 31,659 | +38.5% | 0.00% | – |
| Q4 2020 | $322,000 | -78.7% | 22,856 | -81.9% | 0.00% | – |
| Q3 2020 | $1,511,000 | -1.2% | 125,951 | +36.7% | 0.00% | – |
| Q2 2020 | $1,530,000 | +294.3% | 92,123 | +170.3% | 0.00% | – |
| Q1 2020 | $388,000 | – | 34,085 | +24962.5% | 0.00% | – |
| Q3 2019 | $0 | – | 136 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
| ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
| EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
| Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
| Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
| Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
| Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
| Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
| PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
| Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |